Kamal Hamed - Jun 12, 2023 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
Chief Medical Officer
Signature
/s/ Tamara Joseph. Attorney-in-Fact for Kamal Hamed
Stock symbol
SPRO
Transactions as of
Jun 12, 2023
Transactions value $
$0
Form type
4
Date filed
6/14/2023, 08:30 AM
Previous filing
Feb 3, 2023
Next filing
Sep 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +140K +29.41% $0.00 616K Jun 12, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 4, 2022, the Reporting Person was granted a target of 140,000 performance-based restricted stock units ("RSUs") under the Issuer's 2019 Inducement Equity Incentive Plan, as amended. Each RSU represents the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On June 12, 2023, the Board of Directors of the Issuer determined that 100% of the performance-based conditions were met resulting in 140,000 RSUs earned by the Reporting Person. The RSUs vest in two equal annual installments on September 12, 2023 and September 12, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Consists of RSUs held by the Reporting Person.